CA2375905A1 - Moyens et methodes pour surveiller un traitement antiretroviral utilisant un inhibiteur de la protease et pour aider a la prise de decisions therapeutiques concernant le traitement du vih/sida - Google Patents

Moyens et methodes pour surveiller un traitement antiretroviral utilisant un inhibiteur de la protease et pour aider a la prise de decisions therapeutiques concernant le traitement du vih/sida Download PDF

Info

Publication number
CA2375905A1
CA2375905A1 CA002375905A CA2375905A CA2375905A1 CA 2375905 A1 CA2375905 A1 CA 2375905A1 CA 002375905 A CA002375905 A CA 002375905A CA 2375905 A CA2375905 A CA 2375905A CA 2375905 A1 CA2375905 A1 CA 2375905A1
Authority
CA
Canada
Prior art keywords
hiv
mutation
codon
patient
protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002375905A
Other languages
English (en)
Inventor
Neil T. Parkin
Rainer A. Ziermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monogram Biosciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/591,899 external-priority patent/US6869759B1/en
Application filed by Individual filed Critical Individual
Publication of CA2375905A1 publication Critical patent/CA2375905A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Cette invention se rapporte à des épreuves de sensibilité et de résistance à un médicament antiviral pouvant être utilisées pour identifier des régimes posologiques efficaces pour le traitement de l'infection par le virus de l'immunodéficience humaine (VIH) ou du syndrome d'immunodéficience acquise (SIDA), notamment des régimes thérapeutiques comprenant un inhibiteur de la protéase. L'invention se rapporte en outre aux moyens et aux méthodes utilisant des épreuves de sensibilité phénotypiques ou génotypiques pour surveiller l'évolution clinique de l'infection à VIH et la réaction de cette dernière à un traitement antirétroviral.
CA002375905A 1999-06-22 2000-06-22 Moyens et methodes pour surveiller un traitement antiretroviral utilisant un inhibiteur de la protease et pour aider a la prise de decisions therapeutiques concernant le traitement du vih/sida Abandoned CA2375905A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33832399A 1999-06-22 1999-06-22
US09/338,323 1999-06-22
US09/591,899 US6869759B1 (en) 1999-06-22 2000-06-12 Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US09/591,899 2000-06-12
PCT/US2000/017178 WO2000078996A1 (fr) 1999-06-22 2000-06-22 Moyens et methodes pour surveiller un traitement antiretroviral utilisant un inhibiteur de la protease et pour aider a la prise de decisions therapeutiques concernant le traitement du vih/sida

Publications (1)

Publication Number Publication Date
CA2375905A1 true CA2375905A1 (fr) 2000-12-28

Family

ID=26991134

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002375905A Abandoned CA2375905A1 (fr) 1999-06-22 2000-06-22 Moyens et methodes pour surveiller un traitement antiretroviral utilisant un inhibiteur de la protease et pour aider a la prise de decisions therapeutiques concernant le traitement du vih/sida

Country Status (5)

Country Link
EP (1) EP1194587A4 (fr)
AU (1) AU5758200A (fr)
BR (1) BR0011939A (fr)
CA (1) CA2375905A1 (fr)
WO (1) WO2000078996A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE302287T1 (de) 1999-05-28 2005-09-15 Virco Nv Neue mutationsprofile der hiv-1 reverse transcriptase in verbindung mit phänotypischem medikamentresistenz
US7138231B2 (en) 2000-09-15 2006-11-21 Monogram Biosciences, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US6869759B1 (en) 1999-06-22 2005-03-22 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US7186506B1 (en) 2000-06-12 2007-03-06 Monogram Biosciences, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
JP5156163B2 (ja) 2000-04-18 2013-03-06 ビルコ・ビーブイビーエイ 薬剤耐性の測定方法
CA2422815A1 (fr) * 2000-09-15 2002-03-21 Virologic, Inc. Moyens et methodes de suivi d'une therapie antiretrovirale a base d'inhibiteurs de proteases et decisions d'orientation therapeutique dans le traitement du vih et du sida
AU2631602A (en) 2000-10-20 2002-04-29 Virco Nv New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
EP1407042A4 (fr) * 2001-06-04 2006-02-22 Virologic Inc Dispositif et methodes de surveillance d'une therapie antiretrovirale inhibitrice de la protease et determination de decisions therapeutiques dans le traitement du vih/sida
US7384734B2 (en) * 2002-02-15 2008-06-10 Monogram Biosciences, Inc. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
CA2490862A1 (fr) 2002-07-01 2004-01-08 Tibotec Pharmaceuticals Ltd. Nouveaux profils mutationnels dans une protease du vih-1 correles a une resistance phenotypique aux medicaments
CA2491388A1 (fr) 2002-07-01 2004-01-08 Virologic, Inc. Compositions et methodes permettant de mesurer la sensibilite d'un virus pathogene a des inhibiteurs de la protease
US7993824B2 (en) 2002-07-01 2011-08-09 Monogram Biosciences, Inc. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
ATE375400T1 (de) * 2002-07-01 2007-10-15 Tibotec Pharm Ltd Neue mutationsmuster in hiv-1 reverser transcriptase, die mit phenotypischer resistenz gegen medikamente korrelieren
WO2004003223A2 (fr) * 2002-07-01 2004-01-08 Tibotec Pharmaceuticals Ltd. Nouveaux profils mutationnels dans une transcriptase inverse du vih-1 correles a une resistance phenotypique aux medicaments
EP2162745A1 (fr) 2007-05-25 2010-03-17 Tibotec Pharmaceuticals Nouveau profil mutationnel dans un site de clivage du gag du vih-1 corrélé à une résistance phénotypique aux médicaments

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766842A (en) * 1994-09-16 1998-06-16 Sepracor, Inc. In vitro method for predicting the evolutionary response of a protein to a drug targeted thereagainst

Also Published As

Publication number Publication date
WO2000078996A1 (fr) 2000-12-28
EP1194587A4 (fr) 2005-07-06
BR0011939A (pt) 2002-03-12
WO2000078996A9 (fr) 2002-07-11
AU5758200A (en) 2001-01-09
EP1194587A1 (fr) 2002-04-10

Similar Documents

Publication Publication Date Title
US20110229906A1 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
CA2375905A1 (fr) Moyens et methodes pour surveiller un traitement antiretroviral utilisant un inhibiteur de la protease et pour aider a la prise de decisions therapeutiques concernant le traitement du vih/sida
US7138231B2 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
CA2341679A1 (fr) Methodes et moyens pour controler une therapie antiretrovirale utilisant l'inhibiteur de la reverse-transcriptase nucleosidique, et pour operer des choix therapeutiques dans le traitement du vih/sida
US6653081B2 (en) Methods for monitoring antiretroviral therapy and guiding therapeutic decision in the treatment of HIV/AIDS
AU772511B2 (en) Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy
AU2001290923A1 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US6869759B1 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
EP1407042A2 (fr) Dispositif et methodes de surveillance d'une therapie antiretrovirale inhibitrice de la protease et determination de decisions therapeutiques dans le traitement du vih/sida
US7186506B1 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US20130274276A1 (en) Methods and compositions for determining virus susceptibility to non-nucleoside reverse transcriptase inhibitors
CA2411401A1 (fr) Systemes et procedes pour le controle de therapie antiretrovirale et l'orientation des decisions therapeutiques dans le traitement du vih/sida
US20050130134A1 (en) Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment HIV-AIDS
EP2522757A1 (fr) Procédés et compositions permettant de déterminer la sensibilité à un médicament anti-VIH et la capacité de réplication du VIH
US7037644B1 (en) Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
AU2007231808A1 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US20020094522A1 (en) Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued